Key result
Optimization of diuretic therapy and correction of neurohormonal disturbances remain the primary therapeutic targets for managing dyspnoea in chronic heart failure.
Why the study?
What are the current pharmacological and nonpharmacological management options for dyspnoea in patients with chronic heart failure?
What are the current pharmacological and nonpharmacological management options for dyspnoea in patients with chronic heart failure?
This review highlights the importance of optimizing diuretic therapy and neurohormonal balance, while noting emerging roles for exercise, mindfulness, and specific pharmacological agents in managing dyspnoea in chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Supports diuretic and neurohormonal optimization as primary targets for dyspnoea in chronic HF; leaves open adjunctive roles for exercise and mindfulness.
Johnson et al. (2010) conducted a review in chronic heart failure (CHF). Management options for dyspnoea was evaluated on dyspnoea. Optimization of diuretic therapy and correction of neurohormonal disturbances remain the primary therapeutic targets for managing dyspnoea in chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: